Journal of Hematopathology

, Volume 12, Issue 3, pp 109–119 | Cite as

Inconsistency associated with SOX11 immunohistochemistry in mantle cell lymphoma: a meta-analysis

  • Woojoo Lee
  • Eun Shin
  • Bo Hyung Kim
  • Hyunchul KimEmail author
Original Article


SOX11 immunohistochemistry (IHC) in mantle cell lymphoma (MCL) is known to show varied results. Our aim was to evaluate the factor responsible for this variation among different studies. A meta-analysis was performed with the original data including the proportion and number of SOX11-positive MCL cases, host and clonality of SOX11 antibodies, clone or catalog number of antibodies, MCL subtypes, number of cases with indolent traits, number of aggressive variants, and cut-off for SOX11 IHC interpretation. A total of 21 published studies were analyzed. The combined proportion of SOX11-positive MCL cases was 0.80 (95% CI = [0.72, 0.87]), and substantial heterogeneity was observed (I2 = 83%). To explore sources of heterogeneity, subgroup analysis and meta-regression were done. Subgroup analysis with moderators of antibody clone or catalog number, antibody clonality, and monoclonal antibody clones showed substantial residual heterogeneity. Meta-regression with moderators of the proportion of cut-off value showed statistically significant result, although that with the aggressive cases did not. However, meta-regression with the cut-off value as a moderator showed substantial heterogeneity. The current meta-analysis of SOX11 immunohistochemistry in MCL showed the cut-off value to be important sources of overall heterogeneity.


SOX11 Immunohistochemistry Mantle cell lymphoma Meta-analysis 


Author’s contributions

W. L.: data analysis and manuscript editing

E. S.: article selection, data extraction, and manuscript editing

B. K.: article selection and data extraction

H. K.: design and manuscript editing

Funding Information

Woojoo Lee was supported by a Grant from the Next-Generation BioGreen 21 program (Project No. PJ01337701), Rural Development Administration, Republic of Korea.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Swerdlow SH (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, Revised fourth edition. International Agency for Research on Cancer. WHO Press, Lyon, France. Geneva, SwitzerlandGoogle Scholar
  2. 2.
    Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Sole F, Lopez-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E (2009) SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94(11):1555–1562. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jay P, Goze C, Marsollier C, Taviaux S, Hardelin JP, Koopman P, Berta P (1995) The human SOX11 gene: cloning, chromosomal assignment and tissue expression. Genomics 29(2):541–545. CrossRefPubMedGoogle Scholar
  4. 4.
    Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA (2008) Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 111(2):800–805. CrossRefPubMedGoogle Scholar
  5. 5.
    Lord M, Wasik AM, Christensson B, Sander B (2015) The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. Haematologica 100(9):e369–e372. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhang LN, Cao X, Lu TX, Fan L, Wang L, Xu J, Zhang R, Zou ZJ, Wu JZ, Li JY, Xu W (2013) Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas. Am J Clin Pathol 140(6):795–800. CrossRefPubMedGoogle Scholar
  7. 7.
    Kimura Y, Sato K, Imamura Y, Arakawa F, Kiyasu J, Takeuchi M, Miyoshi H, Yoshida M, Niino D, Sugita Y, Morito T, Yoshino T, Nakamura S, Ohshima K (2011) Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. Cancer Sci 102(9):1734–1741. CrossRefPubMedGoogle Scholar
  8. 8.
    Chen YH, Gao J, Fan G, Peterson LC (2010) Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 23(1):105–112. CrossRefPubMedGoogle Scholar
  9. 9.
    Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, Delabie J, Naresh KN, Bagg A, Brousset P, Warnke RA, Serrano S, Harris NL, Swerdlow SH, Jaffe ES, Campo E (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2):270–278. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chuang WY, Chang H, Chang GJ, Wang TH, Chang YS, Wang TH, Yeh CJ, Ueng SH, Chien HP, Chang CY, Wan YL, Hsueh C (2017) Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology 70(6):986–999. CrossRefPubMedGoogle Scholar
  11. 11.
    Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, Mace A, Leventoux N, Costes V, Szablewski V (2016) Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Archiv 469(6):697–706. CrossRefPubMedGoogle Scholar
  12. 12.
    Hsi AC, Hurley MY, Lee SJ, Rosman IS, Pang X, Gru A, Schaffer A (2016) Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas. J Cutan Pathol 43(4):354–361. CrossRefPubMedGoogle Scholar
  13. 13.
    Hsiao SC, Cortada IR, Colomo L, Ye H, Liu H, Kuo SY, Lin SH, Chang ST, Kuo TU, Campo E, Chuang SS (2012) SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 61(4):685–693. CrossRefPubMedGoogle Scholar
  14. 14.
    Nakashima MO, Durkin L, Bodo J, Lin J, Quintanilla-Martinez L, Fu K, Hsi ED (2014) Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl Immunohistochem Mol Morphol 22(10):720–727. CrossRefPubMedGoogle Scholar
  15. 15.
    O'Malley DP, Lee JP, Bellizzi AM (2017) Expression of LEF1 in mantle cell lymphoma. Ann Diagn Pathol 26:57–59. CrossRefPubMedGoogle Scholar
  16. 16.
    Righi S, Pileri S, Agostinelli C, Bacci F, Spagnolo S, Sabattini E (2017) Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. Hum Pathol 59:94–101. CrossRefPubMedGoogle Scholar
  17. 17.
    Roisman A, Huaman Garaicoa F, Metrebian F, Narbaitz M, Kohan D, Garcia Rivello H, Fernandez I, Pavlovsky A, Pavlovsky M, Hernandez L, Slavutsky I (2016) SOXC and MiR17–92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. Genes Chromosom Cancer 55(6):531–540. CrossRefPubMedGoogle Scholar
  18. 18.
    Soldini D, Valera A, Sole C, Palomero J, Amador V, Martin-Subero JI, Ribera-Cortada I, Royo C, Salaverria I, Bea S, Gonzalvo E, Johannesson H, Herrera M, Colomo L, Martinez A, Campo E (2014) Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol 38(1):86–93. CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang YH, Liu J, Dawlett M, Guo M, Sun X, Gong Y (2014) The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples. Cancer Cytopathol 122(12):892–897. CrossRefPubMedGoogle Scholar
  20. 20.
    Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, Goswami M, Wang M, Jorgensen JL, Medeiros LJ, Wang SA (2018) CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 31(2):327–336. CrossRefPubMedGoogle Scholar
  21. 21.
    Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D (2017) Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol 28(10):2489–2495. CrossRefPubMedGoogle Scholar
  22. 22.
    Gong Y, Zhang X, Chen R, Wei Y, Zou Z, Chen X (2017) Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma. PeerJ 5:e3457. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Shih AR, Bledsoe JR, McKelvie P, Louissaint A, Harris NL, Zukerberg L (2017) CD5-negative mantle cell lymphoma shows a less aggressive outcome and variable SOX11 staining. J Hematop 10(2):49–53. CrossRefGoogle Scholar
  24. 24.
    Ondrejka SL, Lai R, Smith SD, Hsi ED (2011) Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96(8):1121–1127. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Nordstrom L, Sernbo S, Eden P, Gronbaek K, Kolstad A, Raty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundstrom C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S (2014) SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol 166(1):98–108. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Core Team R (2017) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
  27. 27.
    Schwarzer G (2007) meta: an R package for meta-analysis. R News 7(3):40–45Google Scholar
  28. 28.
    Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from Retrieved 31 Jan 2019
  29. 29.
    Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18(20):2693–2708CrossRefPubMedGoogle Scholar
  30. 30.
    Nordstrom L, Andreasson U, Jerkeman M, Dictor M, Borrebaeck C, Ek S (2012) Expanded clinical and experimental use of SOX11 - using a monoclonal antibody. BMC Cancer 12:269. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, Hernandez L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, Lopez-Guillermo A, Jares P, Serrano S, Campo E (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70(4):1408–1418. CrossRefPubMedGoogle Scholar
  32. 32.
    Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED (2012) Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol 36(2):214–219. CrossRefPubMedGoogle Scholar
  33. 33.
    Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Pospisilova H, Minnei F, Verhoef G, Thomas J, Vandenberghe P, De Wolf-Peeters C (2008) Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111(12):5683–5690. CrossRefPubMedGoogle Scholar
  34. 34.
    Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, Song JY, Woroniecka R, Rymkiewicz G, Klapper W, Hartmann EM, Sujobert P, Wlodarska I, Ferry JA, Gaulard P, Ott G, Rosenwald A, Lopez-Guillermo A, Quintanilla-Martinez L, Harris NL, Jaffe ES, Siebert R, Campo E, Bea S (2013) CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma. Blood 121(8):1394–1402. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cao X, Fan L, Fang C, Zhu DX, Dong HJ, Wang DM, Wang YH, Xu W, Li JY (2012) The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases. Med Oncol (Northwood, London, England) 29(2):1190–1196. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of StatisticsInha UniversityIncheonRepublic of Korea
  2. 2.Department of PathologyHallym University Dongtan Sacred Heart HospitalHwaseong-siRepublic of Korea
  3. 3.Department of Clinical Pharmacology and TherapeuticsKyung Hee University College of Medicine and HospitalSeoulRepublic of Korea
  4. 4.Department of Biomedical Science and Technology, Graduate SchoolKyung Hee UniversitySeoulRepublic of Korea

Personalised recommendations